Assessing Patient Engagement in Keratoconus Clinical Research
Exploring Enrollment and Engagement Trends in Individuals Managing Keratoconus: A Comprehensive Examination of Data on Keratoconus Clinical Trials
1 other identifier
observational
500
1 country
1
Brief Summary
This study aims to investigate the influences behind patient choices regarding involvement, discontinuation, or re-engagement in keratoconus clinical trials. Uncovering these factors is essential to enhance the relevance and efficacy of future research endeavors. In essence, this trial aims to deepen understanding of the factors influencing participation in keratoconus clinical trials. Elevating participation rates could expedite the development of innovative treatments for this challenging condition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 23, 2024
CompletedFirst Posted
Study publicly available on registry
March 1, 2024
CompletedStudy Start
First participant enrolled
March 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2027
ExpectedMarch 1, 2024
February 1, 2024
1 year
February 23, 2024
February 23, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Rate of patients who decide to join in a keratoconus clinical trial
3 months
Number of keratoconus patients who remain in clinical trial until completion
12 months
Eligibility Criteria
Patients with keratoconus who are actively considering enrolling in a clinical study, but have not yet completed enrollment and randomization.
You may qualify if:
- Signed Written Informed Consent
- Aged ≥ 18 years old
- No prior treatment for keratoconus
You may not qualify if:
- Participant is actively receiving study therapy in another
- Inability to provide written informed consent
- Women of childbearing potential without a negative pregnancy test; or women who are lactating.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Power Life Sciences
San Francisco, California, 94107, United States
Related Publications (3)
Moran S, Gomez L, Zuber K, Gatinel D. A Case-Control Study of Keratoconus Risk Factors. Cornea. 2020 Jun;39(6):697-701. doi: 10.1097/ICO.0000000000002283.
PMID: 32040008BACKGROUNDKandel H, Pesudovs K, Nguyen V, Chen JY, Poon A, Mills R, Watson SL. Patient-Reported Outcomes in Keratoconus: A Save Sight Keratoconus Registry Study. Cornea. 2023 May 1;42(5):590-597. doi: 10.1097/ICO.0000000000003119. Epub 2022 Aug 24.
PMID: 36036705BACKGROUNDAiello F, Gallo Afflitto G, Ceccarelli F, Garzione F, Pocobelli G, Pinci C, Di Lorenzo G, Siracusano A, Nucci C. Keratoconus and Personality Traits: A Case-Control Study. Cornea. 2024 Feb 1;43(2):237-244. doi: 10.1097/ICO.0000000000003284. Epub 2023 Apr 5.
PMID: 37018764BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Michael B Gill
Power Life Sciences Inc.
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 23, 2024
First Posted
March 1, 2024
Study Start
March 1, 2025
Primary Completion
March 1, 2026
Study Completion (Estimated)
March 1, 2027
Last Updated
March 1, 2024
Record last verified: 2024-02